Dipal Doshi, Entrada Therapeutics CEO

En­tra­da hit with clin­i­cal hold on Duchenne drug

When En­tra­da Ther­a­peu­tics un­veiled its shiny new al­liance with Ver­tex days ago sur­round­ing my­oton­ic dy­s­tro­phy Type I, CEO Di­pal Doshi took the op­por­tu­ni­ty to spot­light a sep­a­rate pro­gram in Duchenne mus­cu­lar dy­s­tro­phy — which he was hop­ing to put in­to the clin­ic in 2023.

But a clin­i­cal hold from the FDA now threat­ens to de­lay those plans.

En­tra­da dis­closed late Mon­day that it re­ceived a clin­i­cal hold no­tice re­gard­ing its pro­gram for EN­TR-601-44, bar­ring it from start­ing a sin­gle as­cend­ing dose study in healthy vol­un­teers. Shares $TR­DA plum­met­ed 32% to $13.50.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.